Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Bogart Wealth LLC

Bogart Wealth LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 193 shares of the medical research company’s stock after selling 52 shares during the quarter. Bogart Wealth LLC’s holdings in Thermo Fisher Scientific were worth $102,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. International Assets Investment Management LLC lifted its position in Thermo Fisher Scientific by 61,995.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after acquiring an additional 1,008,045 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Thermo Fisher Scientific by 17,046.7% in the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after purchasing an additional 967,913 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Thermo Fisher Scientific by 2,567.5% in the fourth quarter. Van ECK Associates Corp now owns 352,217 shares of the medical research company’s stock worth $186,954,000 after purchasing an additional 339,013 shares during the period. Rathbones Group PLC raised its holdings in shares of Thermo Fisher Scientific by 111.0% during the third quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after purchasing an additional 299,338 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 20.3% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock valued at $863,617,000 after buying an additional 287,446 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $564.72, for a total value of $5,647,200.00. Following the completion of the sale, the chief executive officer now owns 128,485 shares in the company, valued at $72,558,049.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last three months, insiders sold 37,711 shares of company stock worth $21,630,972. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have weighed in on TMO shares. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada lifted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Raymond James raised their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, HSBC lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Stock Up 0.1 %

NYSE:TMO traded up $0.77 during mid-day trading on Wednesday, reaching $573.64. The stock had a trading volume of 1,585,506 shares, compared to its average volume of 1,549,346. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a market cap of $218.97 billion, a P/E ratio of 36.80, a PEG ratio of 2.37 and a beta of 0.80. The business’s 50 day moving average is $575.72 and its 200 day moving average is $535.12. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.